Durham-based Atsena Therapeutics, a gene therapy company developing novel treatments to prevent or reverse certain types of inherited blindness, has raised about $24.5 million in private investment and aims to raise about $7.5 million more. Here’s a deep dive into the company and its progress.
Read More
Atsena Therapeutics – a clinical-stage gene therapy company that’s fighting to reverse and prevent blindness and recently launched a clinical trial for a possible treatment, has landed $24.5 million from investors to carry on the battle.
Read More
Meet Atsena Therapeutics – a clinical-stage gene therapy company headquartered in Durham that’s on a mission to reverse and prevent blindness.
Read More
Atsena founder and chief scientific officer Shannon Boye, Ph.D., and founder and chief technology officer Sanford Boye created the therapy at the University of Florida, from which Sanofi originally licensed it.
Read More
